The iBio Technology has been validated by major industry players, as well as the Brazilian government, opening iBio’s doorway to the world market.
With extensive patent protection and proprietary know-how, iBio creates a high barrier to entry for competitors.
iBio’s global commercialization program, which was started in the favorable Brazilian market, is also licening the iBio Technology to key U.S. companies.
The iBio Technology platform is a proprietary gene expression technology that causes non-transgenic plants to rapidly produce high levels of target proteins and has been validated across a wide range of applications in both vaccines and biotherapeutics.

Newark, US
Size (employees)
7 (est)
iBio was founded in 2008 and is headquartered in Newark, US

iBio Office Locations

iBio has an office in Newark
Newark, US (HQ)
100 9 Innovation Way

iBio Data and Metrics

iBio Financial Metrics

iBio's revenue was reported to be $948 k in FY, 2016 which is a 49% decrease from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

948 k

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

(10.7 m)

EBIT (FY, 2016)

(9.9 m)

Market capitalization (26-May-2017)

33 m

Closing share price (26-May-2017)


Cash (31-Dec-2016)

23 m
iBio's current market capitalization is $33 m.
Numbers are in $, USDFY, 2014FY, 2015FY, 2016


205 k1.9 m948 k

Revenue growth, %


R&D expense

1.9 m3.5 m3.2 m

General and administrative expense

3.9 m5 m7.7 m

Operating expense total

4 m8.5 m10.8 m


(3.8 m)(6.7 m)(9.9 m)

EBIT margin, %


Interest income

8 k9 k22 k

Net Income

(3.7 m)(6.6 m)(10.7 m)
Numbers are in $, USDFY, 2014FY, 2015FY, 2016


3.6 m9.5 m23 m


118 k182 k264 k

Current Assets

3.9 m10.1 m23.9 m


6 k13 k25.6 m

Total Assets

6.5 m12.5 m51.6 m

Accounts Payable

297 k1.1 m1.2 m

Additional Paid-in Capital

47.2 m59 m67.5 m

Retained Earnings

(41.2 m)(47.8 m)(57.6 m)

Total Equity

6.1 m11.2 m24 m

Financial Leverage

1.1 x1.1 x2.1 x
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Net Income

(3.7 m)(6.6 m)(10.7 m)

Depreciation and Amortization

361 k363 k940 k


97 k(64 k)(82 k)

Accounts Payable

56 k806 k(125 k)

Cash From Operating Activities

(4.1 m)(4.7 m)(8.1 m)

Cash From Investing Activities

(259 k)(215 k)(68 k)

Cash From Financing Activities

3.6 m10.9 m21.7 m
Numbers are in $, USDY, 2016


135.4 k

Financial Leverage

2.1 x

iBio Operating Metrics

FY, 2016

Patents Issued


Patents Pending


iBio Market Value History

iBio Revenue Breakdown

iBio News and Updates

iBio Company Life and Culture

You may also be interested in